The Trump administration has stated its goal of aggressively pursuing health care fraud.

By focusing on these overlooked challenges, DME providers can improve their operational stability, financial position, and most of all, their quality of care.

Stock and bill arrangements are acceptable under the law—so long as they are not merely a subterfuge to funnel something of value to referral sources.

Health insurers have pledged a set of voluntary reforms aimed at simplifying the prior authorization process.

CMS has recently initiated a surge in off-cycle, unannounced site visits nationwide.

A DME supplier lives in a glass house. If the supplier is doing something it should not be doing, somebody knows about it.